Meribank Biotech Co., Ltd (TPEX:4724)

Market Cap	1.30B -39.8%
Revenue (ttm)	486.52M +86.0%
Net Income	-66.84M
EPS	-0.76
Shares Out	87.98M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	68,440
Average Volume	83,702
Open	14.80
Previous Close	14.80
Day's Range	14.35 - 14.85
52-Week Range	13.90 - 24.75
Beta	0.47
RSI	36.21
Earnings Date	Mar 20, 2026

About Meribank Biotech

Meribank Biotech Co., Ltd researches, develops, manufactures, and stores mesenchymal stem cells in Taiwan. The company engages in the detection, extraction, cryopreservation, archiving, and storage of umbilical cord blood, placental and umbilical cord mesenchymal stem cells, adult peripheral blood stem cells, and immune cells. It also provides cell cryopreservation services. The company was founded in 2001 and is based in Taipei City, Taiwan.

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2001
• Employees: 142
• Stock Exchange: Taipei Exchange
• Ticker Symbol: 4724

Financial Performance

In 2024, Meribank Biotech's revenue was 366.43 million, an increase of 56.37% compared to the previous year's 234.34 million. Losses were -94.71 million, -24.44% less than in 2023.